First Case Performed Using Natus XactTrode™ Subdural Electrodes
Natus Medical (NASDAQ:NTUS) has successfully completed its first clinical case using the newly launched XactTrode™ family of platinum subdural electrodes, aimed at epilepsy surgical monitoring.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Natus Medical (NASDAQ:NTUS) has successfully completed its first clinical case using the newly launched XactTrode™ family of platinum subdural electrodes, aimed at epilepsy surgical monitoring. These electrodes are designed for temporary use (30 days) to capture and stimulate electrical signals on the brain's surface. CEO Jonathan Kennedy expressed satisfaction with their performance and compatibility with Natus’ Quantum system, enhancing operational efficiency for healthcare teams. The XactTrodes are now available to enhance surgical options for patients with central nervous system disorders.
Positive
- Successful clinical case completed with XactTrode electrodes.
- XactTrodes designed for superior anatomical fit and signal performance.
- Compatible with Natus' leading Quantum system for improved efficiency.
Negative
- None.
Details
News Market Reaction – NTUS
The recorded move for NTUS in the trading session of this news was -0.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Launch to US Market of XactTrodes for Epilepsy Surgical Monitoring
PLEASANTON, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, is pleased to announce the completion of the first successfully performed clinical case using Natus’ newly launched XactTrode™ family of platinum subdural electrodes. The Natus XactTrodes are intended for temporary (< 30 days) use with recording, monitoring and stimulation of electrical signals on the surface of the brain.
“We are pleased that the surgical team found the XactTrodes to be an excellent solution for both anatomic fit and signal performance,” says Jonathan Kennedy, Natus CEO. “Natus is thrilled to now offer XactTrodes to our customers. We designed them to work seamlessly with our market leading Quantum system, which will provide care teams greater efficiency and performance.”
For more information about XactTrodes, please visit https://neuro.natus.com/products-services/subdural-electrodes.
About Natus Medical Incorporated
Natus Medical Incorporated improves patient outcomes using the most comprehensive product solutions, depth of training and continuing customer care when diagnosing and treating central nervous and sensory system disorders for patients of all ages.
Additional information about Natus Medical Incorporated can be found at https://natus.com.
Contacts:
Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.